ZA201504952B - Human antibodies to respiratory syncytial virus f protein and methods - Google Patents
Human antibodies to respiratory syncytial virus f protein and methodsInfo
- Publication number
- ZA201504952B ZA201504952B ZA2015/04952A ZA201504952A ZA201504952B ZA 201504952 B ZA201504952 B ZA 201504952B ZA 2015/04952 A ZA2015/04952 A ZA 2015/04952A ZA 201504952 A ZA201504952 A ZA 201504952A ZA 201504952 B ZA201504952 B ZA 201504952B
- Authority
- ZA
- South Africa
- Prior art keywords
- protein
- methods
- human antibodies
- respiratory syncytial
- syncytial virus
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1027—Paramyxoviridae, e.g. respiratory syncytial virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C07K16/11—
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56983—Viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
- C12N2760/18521—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
- G01N2333/08—RNA viruses
- G01N2333/115—Paramyxoviridae, e.g. parainfluenza virus
- G01N2333/135—Respiratory syncytial virus
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Virology (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Pulmonology (AREA)
- Biochemistry (AREA)
- Mycology (AREA)
- Communicable Diseases (AREA)
- Neurology (AREA)
- Oncology (AREA)
- Analytical Chemistry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Pain & Pain Management (AREA)
- Neurosurgery (AREA)
- Heart & Thoracic Surgery (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361782215P | 2013-03-14 | 2013-03-14 | |
| US201361911093P | 2013-12-03 | 2013-12-03 | |
| PCT/US2014/025259 WO2014159822A2 (en) | 2013-03-14 | 2014-03-13 | Human antibodies to respiratory syncytial virus f protein and methods of use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA201504952B true ZA201504952B (en) | 2016-07-27 |
Family
ID=50391532
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA2015/04952A ZA201504952B (en) | 2013-03-14 | 2015-07-09 | Human antibodies to respiratory syncytial virus f protein and methods |
Country Status (19)
Families Citing this family (68)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI659968B (zh) | 2013-03-14 | 2019-05-21 | 再生元醫藥公司 | 針對呼吸道融合病毒ｆ蛋白質的人類抗體及其使用方法 |
| AR095196A1 (es) | 2013-03-15 | 2015-09-30 | Regeneron Pharma | Medio de cultivo celular libre de suero |
| CA2963037A1 (en) | 2014-10-10 | 2016-04-14 | Ablynx N.V. | Treatment of rsv infection |
| PT3204095T (pt) | 2014-10-10 | 2019-07-11 | Ablynx Nv | Dispositivo de inalação para usar na terapia com aerossóis de doenças respiratórias |
| US9340604B1 (en) * | 2014-10-29 | 2016-05-17 | Aridis Pharmaceuticals, Inc. | Human monoclonal antibody specific for the F protein of respiratory syncytial virus (RSV) |
| CN107810231B (zh) | 2015-06-25 | 2020-10-16 | Sabic环球技术有限责任公司 | 包含直链低密度聚乙烯的聚合物组合物 |
| EP3317290A4 (en) * | 2015-07-02 | 2019-04-10 | Spring Bank Pharmaceuticals, Inc. | COMPOSITIONS AND METHOD FOR TREATING VIRUS INFECTION |
| TWI870789B (zh) | 2015-08-04 | 2025-01-21 | 美商再生元醫藥公司 | 補充牛磺酸之細胞培養基及用法 |
| JO3555B1 (ar) | 2015-10-29 | 2020-07-05 | Merck Sharp & Dohme | جسم مضاد يبطل فعالية فيروس الالتهاب الرئوي البشري |
| CN106496324B (zh) * | 2015-11-30 | 2020-01-14 | 天津昊免生物技术有限公司 | 一种抗呼吸道合胞病毒的全人源抗体 |
| EP3504328A1 (en) | 2016-08-24 | 2019-07-03 | Regeneron Pharmaceuticals, Inc. | Host cell protein modification |
| WO2018075954A2 (en) | 2016-10-21 | 2018-04-26 | Adimab, Llc | Anti-respiratory syncytial virus antibodies, and methods of their generation and use |
| AU2017345786B2 (en) | 2016-10-21 | 2024-08-01 | Adimab, Llc | Anti-respiratory syncytial virus antibodies, and methods of their generation and use |
| SG11201903287PA (en) * | 2016-10-21 | 2019-05-30 | Adimab Llc | Anti-respiratory syncytial virus antibodies, and methods of their generation and use |
| US10259865B2 (en) | 2017-03-15 | 2019-04-16 | Adma Biologics, Inc. | Anti-pneumococcal hyperimmune globulin for the treatment and prevention of pneumococcal infection |
| MX2020000228A (es) | 2017-07-06 | 2020-08-10 | Regeneron Pharma | Proceso de cultivo celular para producir una glicoproteina. |
| EP3695003A4 (en) * | 2017-10-13 | 2021-12-22 | Adimab, LLC | ANTIBODIES TO RESPIRATORY SYNCYTIAL VIRUS AND METHOD OF GENERATING AND USING THEREOF |
| CN115925882A (zh) | 2017-12-22 | 2023-04-07 | 瑞泽恩制药公司 | 用于表征药物产品杂质的系统和方法 |
| CN111655722A (zh) | 2018-01-31 | 2020-09-11 | 瑞泽恩制药公司 | 用于表征药物产品杂质的系统和方法 |
| JP2021512600A (ja) * | 2018-01-31 | 2021-05-20 | ザ ウィスター インスティテュート オブ アナトミー アンド バイオロジー | 呼吸器合胞体ウイルスに対して使用するための核酸抗体構築物 |
| TWI786265B (zh) | 2018-02-02 | 2022-12-11 | 美商再生元醫藥公司 | 用於表徵蛋白質二聚合之系統及方法 |
| CA3088906A1 (en) | 2018-02-28 | 2019-09-06 | Regeneron Pharmaceuticals, Inc. | Systems and methods for identifying viral contaminants |
| US12253490B2 (en) | 2018-03-19 | 2025-03-18 | Regeneron Pharmaceuticals, Inc. | Microchip capillary electrophoresis assays and reagents |
| US12259355B2 (en) | 2018-03-19 | 2025-03-25 | Regeneron Pharmaceuticals, Inc. | Microchip capillary electrophoresis assays and reagents |
| CN111868085B (zh) | 2018-03-19 | 2024-11-05 | 瑞泽恩制药公司 | 微芯片毛细管电泳测定法及试剂 |
| TW202016125A (zh) | 2018-05-10 | 2020-05-01 | 美商再生元醫藥公司 | 用於定量及調節蛋白質黏度之系統與方法 |
| JP2021535739A (ja) | 2018-08-27 | 2021-12-23 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 下流精製でのラマン分光法の使用 |
| KR20210053816A (ko) | 2018-08-30 | 2021-05-12 | 리제너론 파마슈티칼스 인코포레이티드 | 단백질 복합체를 특성화하기 위한 방법 |
| CN117838855A (zh) * | 2018-09-21 | 2024-04-09 | 北卡罗来纳大学查佩尔希尔分校 | 限制穿过黏液的合成粘合剂 |
| WO2020124846A1 (zh) * | 2018-12-18 | 2020-06-25 | 珠海泰诺麦博生物技术有限公司 | 抗呼吸道合胞病毒的中和抗体及其应用 |
| EP4220173A3 (en) | 2019-01-16 | 2023-10-18 | Regeneron Pharmaceuticals, Inc. | Methods for characterizing disulfide bonds |
| CN111606993B (zh) * | 2019-02-26 | 2022-06-28 | 中国科学院上海生命科学研究院 | 抗呼吸道合胞病毒的全人广谱中和抗体4f1及其应用 |
| KR20220007586A (ko) | 2019-05-13 | 2022-01-18 | 리제너론 파마슈티칼스 인코포레이티드 | 개선된 경쟁적 리간드 결합 검정 |
| KR20220066393A (ko) | 2019-09-24 | 2022-05-24 | 리제너론 파아마슈티컬스, 인크. | 크로마토그래피의 사용 및 재생을 위한 시스템 및 방법 |
| US12297451B1 (en) | 2019-10-25 | 2025-05-13 | Regeneron Pharmaceuticals, Inc. | Cell culture medium |
| AU2020394428B2 (en) | 2019-11-25 | 2025-11-20 | Regeneron Pharmaceuticals, Inc. | Sustained release formulations using non-aqueous emulsions |
| AU2021209866B2 (en) | 2020-01-21 | 2023-07-06 | Regeneron Pharmaceuticals, Inc. | Deglycosylation methods for electrophoresis of glycosylated proteins |
| MX2023002417A (es) | 2020-08-31 | 2023-03-22 | Regeneron Pharma | Estrategias de suministro de asparagina para mejorar el rendimiento del cultivo celular y mitigar las variantes de secuencia de asparagina. |
| FR3114970B1 (fr) * | 2020-10-08 | 2023-06-30 | Univ Tours | Combinaison d’anticorps inhalés avec des agents immunomodulateurs pour le traitement ou la prévention d’inféctions respiratoires |
| IL303027A (en) | 2020-11-25 | 2023-07-01 | Regeneron Pharma | Sustained release formulations by creating a non-aqueous membrane emulsion |
| EP4262757A1 (en) | 2020-12-17 | 2023-10-25 | Regeneron Pharmaceuticals, Inc. | Fabrication of protein-encapsulating microgels |
| JP2024503408A (ja) | 2021-01-20 | 2024-01-25 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 細胞培養におけるタンパク質力価の改善方法 |
| AU2022230987A1 (en) | 2021-03-03 | 2023-08-31 | Regeneron Pharmaceuticals, Inc. | Systems and methods for quantifying and modifying protein viscosity |
| AU2022243005A1 (en) | 2021-03-26 | 2023-10-05 | Regeneron Pharmaceuticals, Inc. | Methods and systems for developing mixing protocols |
| EP4348234A1 (en) | 2021-06-01 | 2024-04-10 | Regeneron Pharmaceuticals, Inc. | Micropchip capillary electrophoresis assays and reagents |
| AR127006A1 (es) | 2021-09-08 | 2023-12-06 | Regeneron Pharma | UN MÉTODO BASADO EN ESPECTROMETRÍA DE MASAS Y DE ALTO RENDIMIENTO PARA CUANTIFICAR ANTICUERPOS Y OTRAS PROTEÍNAS QUE CONTIENEN Fc |
| KR20240058201A (ko) | 2021-09-20 | 2024-05-03 | 리제너론 파마슈티칼스 인코포레이티드 | 항체 이질성을 제어하는 방법 |
| WO2023059800A2 (en) | 2021-10-07 | 2023-04-13 | Regeneron Pharmaceuticals, Inc. | Systems and methods of ph modeling and control |
| CN118076885A (zh) | 2021-10-07 | 2024-05-24 | 里珍纳龙药品有限公司 | pH计校准与校正 |
| WO2023076340A1 (en) | 2021-10-26 | 2023-05-04 | Regeneron Pharmaceuticals, Inc. | Systems and methods for generating laboratory water and distributing laboratory water at different temperatures |
| TW202346856A (zh) | 2022-03-18 | 2023-12-01 | 美商里珍納龍藥品有限公司 | 分析多肽變體的方法及系統 |
| CN120418653A (zh) | 2022-12-16 | 2025-08-01 | 里珍纳龙药品有限公司 | 评估色谱柱完整性的方法和系统 |
| EP4655595A1 (en) | 2023-01-25 | 2025-12-03 | Regeneron Pharmaceuticals, Inc. | Mass spectrometry-based characterization of antibodies co-expressed in vivo |
| TW202445135A (zh) | 2023-01-25 | 2024-11-16 | 美商再生元醫藥公司 | 液態蛋白質組成物穩定性之建模方法 |
| TW202445138A (zh) | 2023-02-01 | 2024-11-16 | 美商再生元醫藥公司 | 用於生物巨分子分析之具質譜法的不對稱流場流分離 |
| EP4669963A2 (en) | 2023-02-22 | 2025-12-31 | Regeneron Pharmaceuticals, Inc. | SYSTEM FITNESS PARAMETERS AND COLUMN AGING |
| AU2024265540A1 (en) | 2023-05-01 | 2025-10-30 | Regeneron Pharmaceuticals, Inc. | Multidose antibody drug products using phenol or benzyl alcohol |
| US20250086164A1 (en) | 2023-09-08 | 2025-03-13 | Regeneron Pharmaceuticals, Inc. | Methods and systems for assessing chromatographic column integrity |
| WO2025064403A2 (en) | 2023-09-18 | 2025-03-27 | Regeneron Pharmaceuticals, Inc. | Methods and systems for developing chromatography protocols |
| TW202532098A (zh) | 2023-09-29 | 2025-08-16 | 美商再生元醫藥公司 | 使用控制成核之冷凍乾燥 |
| WO2025085594A1 (en) | 2023-10-18 | 2025-04-24 | Regeneron Pharmaceuticals, Inc. | Rapid purification of monoclonal antibody from in-process upstream cell culture material |
| TW202535934A (zh) | 2023-11-02 | 2025-09-16 | 美商再生元醫藥公司 | 利用應力來降低脂酶活性的方法 |
| WO2025104604A1 (en) | 2023-11-14 | 2025-05-22 | Janssen Pharmaceuticals, Inc. | Anti-respiratory syncytial virus antibodies and uses thereof |
| WO2025166281A1 (en) | 2024-02-01 | 2025-08-07 | Regeneron Pharmaceuticals, Inc. | Platform for charge-detection mass spectrometry analysis of aavs |
| WO2025175164A1 (en) | 2024-02-16 | 2025-08-21 | Regeneron Pharmaceuticals, Inc. | Methods of producing concentrated formulated drug substances comprising proteins, and concentrated formulated drug substance made by the methods |
| WO2025194043A1 (en) | 2024-03-15 | 2025-09-18 | Regeneron Pharmaceuticals, Inc. | Polysorbate and polyoxyethylene sorbitan as excipients for stable protein formulations |
| WO2025194126A1 (en) * | 2024-03-15 | 2025-09-18 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Respiratory syncytial virus (rsv) g and f antibodies with high rsv-neutralizing potency |
| WO2025259840A1 (en) | 2024-06-13 | 2025-12-18 | Regeneron Pharmaceuticals, Inc. | Methods and systems for scaled chromatography |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5824307A (en) | 1991-12-23 | 1998-10-20 | Medimmune, Inc. | Human-murine chimeric antibodies against respiratory syncytial virus |
| ES2191016T3 (es) | 1992-09-16 | 2003-09-01 | Scripps Research Inst | Anticuerpos monoclonales neutralizantes humanos para el virus respiratorio sincitial. |
| US5811524A (en) | 1995-06-07 | 1998-09-22 | Idec Pharmaceuticals Corporation | Neutralizing high affinity human monoclonal antibodies specific to RSV F-protein and methods for their manufacture and therapeutic use thereof |
| EP0853487B1 (en) | 1995-09-18 | 2000-07-05 | Intracel Corporation | Neutralizing monoclonal antibodies to respiratory syncytial virus |
| CO5280147A1 (es) | 1999-05-18 | 2003-05-30 | Smithkline Beecham Corp | Anticuerpo humano monoclonal |
| US6750008B1 (en) | 1999-07-09 | 2004-06-15 | Trimeris, Inc. | Methods and compositions for inhibition of membrane fusion-associated events, including HIV transmission |
| EP1265928B1 (en) | 2000-01-27 | 2010-07-21 | Medimmune, LLC | Ultra high affinity rsv neutralizing antibodies |
| CA2401652A1 (en) | 2000-03-01 | 2001-09-07 | Medimmune, Inc. | High potency recombinant antibodies and method for producing them |
| US6855493B2 (en) * | 2000-11-28 | 2005-02-15 | Medimmune, Inc. | Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment |
| US20060083741A1 (en) | 2004-10-08 | 2006-04-20 | Hoffman Rebecca S | Treatment of respiratory syncytial virus (RSV) infection |
| EP2004686A1 (en) | 2006-03-06 | 2008-12-24 | Symphogen A/S | Recombinant polyclonal antibody for treatment of respiratory syncytial virus infections |
| EP1997830A1 (en) | 2007-06-01 | 2008-12-03 | AIMM Therapeutics B.V. | RSV specific binding molecules and means for producing them |
| CN101808663B (zh) | 2007-10-25 | 2015-09-30 | 特雷利斯生物科学股份有限公司 | 抗rsv g蛋白抗体 |
| US8852608B2 (en) * | 2009-02-02 | 2014-10-07 | Medimmune, Llc | Antibodies against and methods for producing vaccines for respiratory syncytial virus |
| EP4218800A1 (en) | 2009-07-15 | 2023-08-02 | GlaxoSmithKline Biologicals S.A. | Rsv f protein compositions and methods for making same |
| JP5762408B2 (ja) | 2009-08-13 | 2015-08-12 | クルセル ホランド ベー ヴェー | ヒト呼吸器合胞体ウイルス（ｒｓｖ）に対する抗体および使用方法 |
| US20110097358A1 (en) | 2009-10-12 | 2011-04-28 | Techno Vax, Inc. | RESPIRATORY SYNCYTIAL VIRUS (RSV) VIRUS-LIKE PARTICLES (VLPs) |
| CN102850454B (zh) * | 2011-09-27 | 2014-06-25 | 上海博沃生物科技有限公司 | 抗呼吸道合胞病毒的人单克隆抗体 |
| ES2657470T3 (es) | 2012-03-20 | 2018-03-05 | Humabs Biomed S.A. | Anticuerpos que neutralizan RSV, MPV y PVM y usos de los mismos |
| DK2950886T3 (da) | 2013-02-01 | 2020-03-23 | Medimmune Llc | Respiratorisk syncytialvirus-f-protein-epitoper |
| TWI659968B (zh) * | 2013-03-14 | 2019-05-21 | 再生元醫藥公司 | 針對呼吸道融合病毒ｆ蛋白質的人類抗體及其使用方法 |
| WO2015010792A1 (en) | 2013-07-24 | 2015-01-29 | Humabs Biomed Sa | Antibodies that potently neutralize rsv and uses thereof |
-
2014
- 2014-03-12 TW TW103108584A patent/TWI659968B/zh not_active IP Right Cessation
- 2014-03-13 UY UY0001035416A patent/UY35416A/es not_active Application Discontinuation
- 2014-03-13 MY MYPI2015702227A patent/MY174772A/en unknown
- 2014-03-13 US US14/207,797 patent/US9447173B2/en active Active
- 2014-03-13 JP JP2016501801A patent/JP6537492B2/ja active Active
- 2014-03-13 WO PCT/US2014/025259 patent/WO2014159822A2/en not_active Ceased
- 2014-03-13 AU AU2014244411A patent/AU2014244411B2/en not_active Ceased
- 2014-03-13 CA CA2904995A patent/CA2904995A1/en not_active Abandoned
- 2014-03-13 CN CN201480014354.XA patent/CN105050622B/zh not_active Expired - Fee Related
- 2014-03-13 SG SG11201505338RA patent/SG11201505338RA/en unknown
- 2014-03-13 SG SG10201610336QA patent/SG10201610336QA/en unknown
- 2014-03-13 EA EA201591771A patent/EA034767B1/ru unknown
- 2014-03-13 EP EP14714125.3A patent/EP2968534B1/en active Active
- 2014-03-13 KR KR1020157021198A patent/KR102211907B1/ko not_active Expired - Fee Related
- 2014-03-13 MX MX2015009416A patent/MX360253B/es active IP Right Grant
- 2014-03-13 BR BR112015019066A patent/BR112015019066A2/pt not_active IP Right Cessation
-
2015
- 2015-07-09 ZA ZA2015/04952A patent/ZA201504952B/en unknown
- 2015-07-13 PH PH12015501558A patent/PH12015501558B1/en unknown
- 2015-07-21 IL IL240067A patent/IL240067A0/en unknown
- 2015-09-10 CL CL2015002570A patent/CL2015002570A1/es unknown
-
2016
- 2016-08-05 US US15/229,567 patent/US10125188B2/en active Active
-
2018
- 2018-10-15 US US16/160,374 patent/US20190031741A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201504952B (en) | Human antibodies to respiratory syncytial virus f protein and methods | |
| IL280155A (en) | Anti- SIGLEC-8 antibodies and methods of using them | |
| IL290547A (en) | Antibodies and methods of use | |
| IL241787B (en) | Human fcrn-binding modified antibodies and methods of their use | |
| ZA201607047B (en) | Human antibodies to middle east respiratory syndrome -coronavirus spike protein | |
| IL244495A0 (en) | Anti-alpha-synuclein antibodies and methods of use | |
| PT3390451T (pt) | Anticorpos humanos caninizados para il-4r alfa humano e canino | |
| IL244643A0 (en) | Anti-ly6e antibodies and methods of use | |
| PT2950886T (pt) | Epítopos de proteína f do vírus sincicial respiratório | |
| HUE046673T2 (hu) | Anti-EpCAM antitestek és alkalmazási eljárások | |
| PL2970492T3 (pl) | Przeciwciała przeciwko ludzkim i psim il-13ra2 | |
| SG11201507230PA (en) | Human antibodies that bind human tnf-alpha and methods of preparing the same | |
| SG11201509450QA (en) | Methods to produce particles comprising therapeutic proteins | |
| TH1501005414A (th) | แอนติบอดีของมนุษย์ต่อเรสไพราทอรีซินไซเทียลไวรัส f โปรตีน และวิธีการใช้ของมัน |